Skip to content
ESMO 2025 special: Prof. Roupret presents the ALBAN study episode artwork

EPISODE · Oct 28, 2025 · 7 MIN

ESMO 2025 special: Prof. Roupret presents the ALBAN study

from EAU Podcast · host European Association of Urology

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Morgan Roupret (FR), on the results of the ALBAN trial. A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG naïve high-risk, non-muscle invasive bladder cancer. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Episode metadata supplied by the publisher feed · Published Oct 28, 2025

Embed this episode

Ready to play

ESMO 2025 special: Prof. Roupret presents the ALBAN study

0:00 7:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of EAU Podcast?

This episode is 7 minutes long.

When was this EAU Podcast episode published?

This episode was published on October 28, 2025.

Can I download this EAU Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!